Rep. Gilbert Ray Cisneros, Jr. Buys Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). In a filing disclosed on February 11th, the Representative disclosed that they had bought between $1,001 and $15,000 in Agios Pharmaceuticals stock on January 29th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of ICF International (NASDAQ:ICFI) on 2/3/2025.
• Purchased $15,001 – $50,000 in shares of CACI International (NYSE:CACI) on 1/31/2025.
• Purchased $50,001 – $100,000 in shares of Hawaiian Electric Industries (NYSE:HE) on 1/31/2025.
• Sold $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 1/30/2025.
• Purchased $1,001 – $15,000 in shares of Intuitive Surgical (NASDAQ:ISRG) on 1/30/2025.
• Purchased $1,001 – $15,000 in shares of SpringWorks Therapeutics (NASDAQ:SWTX) on 1/29/2025.
• Purchased $1,001 – $15,000 in shares of Paragon 28 (NYSE:FNA) on 1/29/2025.
• Purchased $1,001 – $15,000 in shares of U.S. Physical Therapy (NYSE:USPH) on 1/29/2025.
• Purchased $1,001 – $15,000 in shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) on 1/29/2025.
• Purchased $1,001 – $15,000 in shares of Lantheus (NASDAQ:LNTH) on 1/28/2025.

Agios Pharmaceuticals Stock Performance

Shares of NASDAQ AGIO traded down $0.47 during mid-day trading on Thursday, reaching $32.35. The company had a trading volume of 168,586 shares, compared to its average volume of 745,298. The stock has a market capitalization of $1.84 billion, a PE ratio of 2.85 and a beta of 0.88. Agios Pharmaceuticals, Inc. has a twelve month low of $24.88 and a twelve month high of $62.58. The stock’s 50 day moving average is $36.28 and its 200-day moving average is $43.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 2,051.38% and a negative return on equity of 2.93%. On average, sell-side analysts anticipate that Agios Pharmaceuticals, Inc. will post -0.46 EPS for the current year.

Analyst Upgrades and Downgrades

AGIO has been the subject of several recent research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. Royal Bank of Canada upped their price objective on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a report on Tuesday, December 10th. Scotiabank raised their target price on Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a report on Monday, December 9th. Finally, StockNews.com upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 9th. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $56.33.

Insider Activity

In other news, insider Tsveta Milanova sold 2,804 shares of the business’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the sale, the insider now owns 18,906 shares in the company, valued at approximately $608,395.08. The trade was a 12.92 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 4.93% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of Agios Pharmaceuticals by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company’s stock valued at $185,045,000 after acquiring an additional 85,339 shares during the period. State Street Corp boosted its stake in Agios Pharmaceuticals by 10.2% during the third quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock worth $103,586,000 after buying an additional 216,484 shares in the last quarter. Erste Asset Management GmbH bought a new position in shares of Agios Pharmaceuticals during the 3rd quarter worth about $97,199,000. Geode Capital Management LLC lifted its stake in Agios Pharmaceuticals by 0.5% during the third quarter. Geode Capital Management LLC now owns 1,357,531 shares of the biopharmaceutical company’s stock worth $60,326,000 after purchasing an additional 6,101 shares during the period. Finally, Frazier Life Sciences Management L.P. boosted its holdings in Agios Pharmaceuticals by 19.7% during the third quarter. Frazier Life Sciences Management L.P. now owns 1,044,154 shares of the biopharmaceutical company’s stock valued at $46,392,000 after purchasing an additional 172,180 shares in the last quarter.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.